Professional Bio
Elizabeth Phillips, MD, MD, FRCPC, FRACP, FIDSA, FAAAAI, is a Professor in the Division of Infectious Diseases, Department of Medicine, and Professor of Dermatology, Pharmacology and Pathology, Microbiology and Immunology at Vanderbilt University Medical Center and Vanderbilt University Medical School. She is the John A. Oates Chair in Clinical Research and Director of Personalized Immunology in the Center for Drug Safety and Immunology. She is a physician scientist clinically trained in infectious diseases, immunology and clinical pharmacology who has established new clinical and research programs in drug hypersensitivity, pharmacogenomics and personalized immunology across different healthcare systems.
Dr. Phillips has published over 350 peer reviewed articles related to hypersensitivity reactions to drugs and vaccines. She is recognized for elucidating mechanisms and genetic determinants of drug hypersensitivity which have transformed research, clinical practice and training in the United States and Internationally. She is PI on an NIH-funded clinical trial, the first randomized double-blinded controlled trial to study the optimal management and mechanisms of SJS/TEN.
Among Dr. Phillips' greatest translational accomplishments between 2002-2008 was leading the development of the HLA-B*57:01 genetic predictor for abacavir hypersensitivity from its discovery through implementation. Her discovery through translation pipeline continues to pioneer strategies to prevent, diagnose and mitigate harm from true drug hypersensitivity and she is applying novel technologies to understand the single cell pathology of drug hypersensitivity at the site of tissue damage leading to identification of new therapeutic targets. She has also led development of clinical practice and guidance dedicated to the care of drug hypersensitivity patients and her clinics have acted as a model for others within the US and internationally.
Dr. Phillips' efforts have transformed care across multiple disciplines and she is a true community leader and advocate for those with severe cutaneous adverse drug reactions, working alongside patients and foundations to advance education, awareness and science of drug hypersensitivity. She was the founder and chair of NIH-funded SJS/TEN meetings in 2017, 2019, 2021 and 2023 and the Inaugural DRESS syndrome 2022 meeting, which actively unite the science and lay communities.
Relevant Links
Publications
Education
MD - University of Alberta, 1989
Internship - General - University of Ottawa, 1990
Residency - Internal Medicine - University of Toronto, 1993
Fellowship - Infectious Disease - University of Toronto, 1995
Fellowship - Medical Microbiology - University of Toronto, 1996
Fellowship - Clinical Pharmacology - University of Toronto, 1998
Fellowship - Research, Clinical Pharmacology - University of Toronto, 1999
Contact
Email
Kimryn.Rathmell@Vumc.Org
Address
777 Preston Research Building
2220 Pierce Ave
Nashville, TN 37232-6307